Abiomed Inc
UPDATE 5-J&J's medical device sales fall short, cancer drugs seen growing
J&J's medical device sales fall short, cancer drugs seen growing. Sales of psoriasis drug Stelara come in lower than expected. The company's large medical devices business reported $7.82 billion in sales for first quarter. J&J shares were down 1.3% in after-hours trading.
Reuters · 04/16 10:30
UPDATE 4-J&J first-quarter revenue misses as Stelara sales fall short
J&J first-quarter revenue misses as sales of psoriasis drug Stelara sales fall short. Sales of cancer drug Darzalex jumped about 19% to $2.69 billion. J&J's medical devices unit reported $7.82 billion in sales for the quarter. The company reported total revenue of $21.38 billion in the first quarter.
Reuters · 04/16 10:30
UPDATE 5-J&J boosts heart device business in $13.1 bln Shockwave deal
J&J to buy Shockwave Medical in a deal valued at $13.1 billion including debt. J&J is building its cardiac-health-centric medical devices business to help drive growth. Shockwave uses shockwaves to break down calcified plaque in heart vessels. The company has offered $335 per share in cash for Shockwave.
Reuters · 04/05 10:41
US FDA classifies recall of Abiomed's blood pumps as most serious
US FDA classifies recall of Abiomed's blood pumps as most serious. Some Impella Left Sided Blood Pumps by Johnson & Johnson could cause serious injuries or death. The recall is classified as the most serious by the U.S. Health regulator.
Reuters · 03/21 14:46

Webull offers Abiomed Inc stock information, including NASDAQ: ABMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABMD stock methods without spending real money on the virtual paper trading platform.